Lewis Thomas Lewis Thomas
"the microorganisms that seem to have it in for us . . . turn out . . . to be rather more like bystanders. . . . It is our response to their presence that makes the disease. Our arsenals for fighting off bacteria are so powerful . . . that we are more in danger from them than the invaders." Germs NEJM 1972; 287:553-5 Patients with severe sepsis or septic shock were randomly assign Patients with severe sepsis or septic shock were randomly assigned ed to get early goal directed therapy vs. standard therapy for the to get early goal directed therapy vs. standard therapy for the first 6 first 6 hours; the physicians were hours; the physicians were " "blinded blinded" " EGDT and standard therapy included CVP (8 EGDT and standard therapy included CVP (8--12 mmHg), MAP (>65 12 mmHg), MAP (>65 mmHg), and UO (>0.5/hr) but EGDT added ScvO mmHg), and UO (>0.5/hr) but EGDT added ScvO 2 2 >70, >70, Hct Hct 30 and 30 and DBA to increase CI to achieve the saturation goal DBA to increase CI to achieve the saturation goal There was a 16% absolute mortality reduction (46.5% vs. 30.5%) There was a 16% absolute mortality reduction (46.5% vs. 30.5%) In the EGDT group O In the EGDT group O 2 saturation was higher, lactate was lower, saturation was higher, lactate was lower, base deficit was lower, pH higher, APACHE II lower and there was base deficit was lower, pH higher, APACHE II lower and there was less severe organ dysfunction less severe organ dysfunction The EGDT got more fluid (3.49 vs. 4.98L), blood (18.5 vs. 64.1%) The EGDT got more fluid (3.49 vs. 4.98L), blood (18.5 vs. 64.1%), , and and Dobutamine Dobutamine (0.8 vs. 13.7%) (0.8 vs. 13.7%) The number needed to treat was 6 The number needed to treat was 6
Results Results
The study was halted at the 2nd interim The study was halted at the 2nd interim eval eval. . Reduction in the relative risk of death by Reduction in the relative risk of death by 19.4% 19.4% Absolute reduction was 6.1% (30.8 vs. 24.7) Absolute reduction was 6.1% (30.8 vs. 24.7) Incidence of serious bleeding was higher in the Incidence of serious bleeding was higher in the treatment group treatment group 3.5% vs. 2% 3.5% vs. 2% The mortality difference was greatest in the The mortality difference was greatest in the sickest patients sickest patients 1 additional life saved for every 16 treated 1 additional life saved for every 16 treated 1 additional serious bleed for every 66 treated 1 additional serious bleed for every 66 treated 
Epidemiology Epidemiology

Intensive Insulin Therapy Intensive Insulin Therapy
Prospective, randomized controlled study of SICU patients on mec Prospective, randomized controlled study of SICU patients on mechanical hanical ventilation ventilation intensive insulin therapy: maintenance of blood glucose at a level between 80 and 110 mg per deciliter conventional treatment: infusion of insulin only if the blood glucose level exceeded 215 mg per deciliter and maintenance of glucose at a level between 180 and 200 mg per deciliter 1548 patients over 12 months Reduced mortality from 8% to 4.6% -Benefit was due to its effect on patients who stayed in the SICU >5 days (20.2% vs.
10.6%)
The greatest reduction in mortality were in those patients that had MODS from a septic focus Reduced In-hospital mortality by 34% Intention--to to--treat analysis of 1200 patients, intensive insulin therapy treat analysis of 1200 patients, intensive insulin therapy reduced blood glucose levels but did not significantly reduce in reduced blood glucose levels but did not significantly reduce in--hospital hospital mortality (40.0 percent in the conventional mortality (40.0 percent in the conventional--treatment group vs. 37.3 treatment group vs. 37.3 percent in the intensive percent in the intensive--treatment group, P=0.33).
treatment group, P=0.33). However, morbidity was significantly reduced by However, morbidity was significantly reduced by --the prevention of newly acquired kidney injury, the prevention of newly acquired kidney injury, --accelerated weaning from mechanical ventilation accelerated weaning from mechanical ventilation --accelerated discharge from the ICU and the hospital. accelerated discharge from the ICU and the hospital.
Length of stay >3 days in the ICU could not be predicted on admi Length of stay >3 days in the ICU could not be predicted on admission ssion Among 433 patients who stayed in the ICU for less than three day Among 433 patients who stayed in the ICU for less than three days, s, mortality was greater among those receiving intensive insulin th mortality was greater among those receiving intensive insulin therapy. erapy. In contrast, among 767 patients who stayed in the ICU for three In contrast, among 767 patients who stayed in the ICU for three or more or more days days
In--hospital mortality in the 386 who received intensive insulin the hospital mortality in the 386 who received intensive insulin therapy was rapy was reduced from 52.5 to 43.0 percent (P=0.009) and morbidity was al reduced from 52.5 to 43.0 percent (P=0.009) and morbidity was also reduced. so reduced.
Conclusions
Conclusions Intensive insulin therapy significantly reduced morbidity but n Intensive insulin therapy significantly reduced morbidity but not ot mortality among all patients in the medical ICU. mortality among all patients in the medical ICU. Although the risk of subsequent death and disease was reduced in Although the risk of subsequent death and disease was reduced in patients patients treated for three or more days, these patients could not be iden treated for three or more days, these patients could not be identified before tified before therapy. therapy.
Van den berghe et al. NEJM 2006;454:449
Steroids and Septic Shock Steroids and Septic Shock
Septic shock may be associated with relative adrenal insufficien Septic shock may be associated with relative adrenal insufficiency; replacement cy; replacement therapy with low doses has been proposed (50 mg of Hydrocortison therapy with low doses has been proposed (50 mg of Hydrocortisone q6h plus e q6h plus 50 50 μ μg of g of fludrocortisone fludrocortisone po po) ) Placebo Placebo--controlled, randomized, double controlled, randomized, double--blind, parallel group trial in 19 ICU blind, parallel group trial in 19 ICU' 's in s in France from 1995 France from 1995--1999 1999 Replacement steroids (n=151) or matching placebo (n=149) were gi Replacement steroids (n=151) or matching placebo (n=149) were given for 7 ven for 7 days; 28 day mortality in the days; 28 day mortality in the nonresponders nonresponders was the main outcome measure was the main outcome measure All the patients had to be septic and in shock and were randomiz All the patients had to be septic and in shock and were randomized from 3 ed from 3--8 8 hours from the onset of shock hours from the onset of shock The patients were then given a 250 The patients were then given a 250 μ μg IV bolus and g IV bolus and cortisol cortisol levels were levels were measures at time 0, 30min, and 60 min after measures at time 0, 30min, and 60 min after Relative adrenal insufficiency was defined as a response of 9 Relative adrenal insufficiency was defined as a response of 9 μ μg/ g/dL dL or less or less There were 229 There were 229 nonresponders nonresponders (115 placebo and 114 steroid) and 70 (115 placebo and 114 steroid) and 70 responders responders The mortality in the placebo group was was 63% and 53% in the st The mortality in the placebo group was was 63% and 53% in the steroid group eroid group Vasopressors Vasopressors were withdrawn in the 57% in the steroid group vs. 40% in the were withdrawn in the 57% in the steroid group vs. 40% in the placebo placebo However, the analysis was done correcting for baseline However, the analysis was done correcting for baseline cortisol cortisol, , cortisol cortisol response, McCabe Classification, LOD score, arterial lactate, an response, McCabe Classification, LOD score, arterial lactate, and P/F ratio d P/F ratio 
Corticus Corticus
Multicenter, randomized, double-blind, placebo-controlled trial 251 patients received 50 mg of intravenous hydrocortisone and 248 patients received placebo every 6 hours for 5 days; then the dose was then tapered during a 6-day period. At 28 days, the primary outcome was death among patients who did not have a response to a corticotropin test. Of the 499 patients in the study, 233 (46.7%) did not have a response to corticotropin (125 in the hydrocortisone group and 108 in the placebo group). At 28 days, there was no significant difference in mortality between patients in the two study groups who did not have a response to corticotropin (39.2% in the hydrocortisone group and 36.1% in the placebo group, P = 0.69) No difference in patients who had a response to corticotropin (28.8% in the hydrocortisone group and 28.7% in the placebo group, P = 1.00). At 28 days, 86 of 251 patients in the hydrocortisone group (34.3%) and 78 of 248 patients in the placebo group (31.5%) had died (P = 0.51).
In the hydrocortisone group, shock was reversed more quickly than in the placebo group. However, there were more episodes of superinfection, including new sepsis and septic shock. Of note the original plan was to recruit 800 patients but had to stop at 500; however it is still the largest study to date Recruitment from 52 centers over 44 months, on average each center took approx 5 months to recruit each patient. The question of clinical equipoise was raised. 
VASST VASST
In this multicenter, randomized, double-blind trial, patients who had septic shock and were receiving a minimum of 5 μg of norepinephrine per minute to receive either low-dose vasopressin (0.01 to 0.03 U per minute) or only norepinephrine (5 to 15 μg per minute) in addition to open-label vasopressors. The primary end point was the mortality rate 28 days after the start of infusions. A total of 778 patients underwent randomization (396 patients received vasopressin, and 382 norepinephrine), and were included in the analysis. There was no significant difference between the vasopressin and norepinephrine groups in the 28-day mortality rate (35.4% and 39.3%, respectively; P = 0.26) or in 90-day mortality (43.9% and 49.6%, respectively; P = 0.11). There were no significant differences in the overall rates of serious adverse events (10.3% and 10.5%, respectively; P = 1.00).
In the prospectively defined stratum of less severe septic shock, the mortality rate was lower in the vasopressin group than in the norepinephrine group at 28 days (26.5% vs. 35.7%, P = 0.05) in the stratum of more severe septic shock, there was no significant difference in 28-day mortality (44.0% and 42.5%, respectively = 0.76). A test for heterogeneity between these two study strata was not significant (P = 0.10). Low-dose vasopressin did not reduce mortality rates as compared with norepinephrine among patients with septic shock who were treated with catecholamine vasopressors. When you are on the wards as a When you are on the wards as a third year student and you have third year student and you have a patient with sepsis a patient with sepsis… …
This was not a primary vasopressor trial
